CD9可预测儿童B细胞前体急性淋巴细胞白血病中的ETV6-RUNX1。
CD9 predicts ETV6-RUNX1 in childhood B-cell precursor acute lymphoblastic leukemia.
作者信息
Blunck Caroline B, Terra-Granado Eugênia, Noronha Elda P, Wajnberg Gabriel, Passetti Fábio, Pombo-de-Oliveira Maria S, Emerenciano Mariana
机构信息
Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil; Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil; Atlantic Cancer Research Institute, Moncton, Canada.
出版信息
Hematol Transfus Cell Ther. 2019 Jul-Sep;41(3):205-211. doi: 10.1016/j.htct.2018.11.007. Epub 2019 Mar 30.
INTRODUCTION
The ETV6-RUNX1 is a fusion gene associated with a good outcome in B-cell precursor lymphoblastic leukemia.
OBJECTIVE
This study aimed to re-evaluate the CD9 cellular expression by flow cytometry (FC) as a possible tool to predict the presence of ETV6-RUNX1.
METHOD
Childhood B-cell precursor lymphoblastic leukemia cases were included (n=186). The percentage of CD9-labeled cells and the median fluorescence intensity ratio were used for correlation with the molecular tests. Receiver Operating Characteristic curves were performed to determine the likelihood of the CD9 expression predicting ETV6-RUNX1.
RESULTS
The ETV6-RUNX1 was found in 44/186 (23.6%) cases. Data analysis revealed that the best cutoff for CD9 percentage was 64%, with an accuracy of 0.84, whereas the best cutoff for CD9 median fluorescence intensity ratio was 12.52, with an accuracy of 0.80. A strong association was observed between the level of CD9 expression and the presence of ETV6-RUNX1.
CONCLUSION
These data confirm that the CD9 expression could be used for risk stratification in clinical practice.
引言
ETV6-RUNX1是一种与B细胞前体淋巴细胞白血病良好预后相关的融合基因。
目的
本研究旨在通过流式细胞术（FC）重新评估CD9细胞表达，作为预测ETV6-RUNX1存在的一种可能工具。
方法
纳入儿童B细胞前体淋巴细胞白血病病例（n=186）。使用CD9标记细胞的百分比和中位荧光强度比值与分子检测进行相关性分析。绘制受试者工作特征曲线以确定CD9表达预测ETV6-RUNX1的可能性。
结果
在44/186（23.6%）例病例中发现了ETV6-RUNX1。数据分析显示，CD9百分比的最佳截断值为64%，准确率为0.84，而CD9中位荧光强度比值的最佳截断值为12.52，准确率为0.80。观察到CD9表达水平与ETV6-RUNX1的存在之间存在强关联。
结论
这些数据证实CD9表达可用于临床实践中的风险分层。
Zotero 插件